Le Lézard
Classified in: Health, Covid-19 virus
Subject: AWD

National Coalition Awarded Over $30 Million to Tackle Opioid Epidemic


EAST PROVIDENCE, R.I., Oct. 22, 2020 /PRNewswire/ -- The American Academy of Addiction Psychiatry (AAAP) has been awarded $16 million each year over two years from the Substance Abuse and Mental Health Services Administration (SAMHSA) to address opioid use disorders and stimulant use disorders. AAAP, with the leadership team at the Addiction Technology Transfer Center at the University of Missouri-Kansas City and Columbia University Division on Substance Use Disorders, will be working collaboratively with an unprecedented coalition of 40 national professional organizations representing over two million constituents.

Recognizing the unique needs of jurisdictions across the country to combat opioid misuse, SAMHSA designed a national training program whose foundation is the use of local teams of experts to deliver tailored training and assistance. The grant supports the ongoing work of the Opioid Response Network initiative, which launched in February 2018. To date, this initiative has reached over 3 million people with education and training to mitigate opioid use, provided at no cost.

"Funding to address the opioid epidemic through localized, evidence-based approaches in the prevention, treatment and recovery of opioid use disorders, stimulant use and other substance use disorders is critical to real change," said Kathryn Cates-Wessel, CEO, AAAP and Principal Investigator for the Opioid Response Network. "Opioid use disorder remains a serious public health concern and appears to have been exacerbated during the current COVID-19 crisis, which is believed to have caused increases in substance use, overdose, depression, anxiety and suicide. The timing for continued support targeting the local needs of communities is now. We thank SAMHSA for their continued support."

Dr. Frances Levin, Opioid Response Network Medical Director and Kennedy-Leavy Professor of Psychiatry at Columbia University Irving Medical Center says: "The Opioid Response Network has been an extremely impactful national initiative that has reached millions of professional colleagues. The alacrity of the network has made it a critically important national resource to help alleviate the persistent public health epidemics of drug overdose, in particular opioid overdose and substance use disorders."

The two-year grant started September 30, 2020. Recognizing the impact stimulant use is having across the country, SAMHSA has required that the network expand resources to provide more educational services in this area. A sampling of the Opioid Response Network's work to date includes:

Any individual, organization, state or city can submit a request to the Opioid Response Network at opioidresponsenetwork.org for education and training tailored specifically to meet their needs at no cost. Requests are responded to within one business day and supported by a technology transfer specialist dedicated to the region.

About the American Academy of Addiction Psychiatry
The American Academy of Addiction Psychiatry (AAAP) is a national professional organization for Addiction Psychiatrists, physicians and allied health professionals dedicated to providing evidence based practices in the education, training, research and policy in the field of substance use disorders and co-occurring mental disorders.

For more information and for media interviews with Opioid Response Network spokespeople in your area, contact:

Jane Goodger, Opioid Response Network Outreach and Communications Manager, [email protected], 401-490-0522

Nic Canning, Opioid Response Network Sr. Project Manager, [email protected], 401-270-1173

SOURCE American Academy of Addiction Psychiatry


These press releases may also interest you

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...



News published on and distributed by: